Secondary Versus Primary Stroke Prevention in Atrial Fibrillation : Insights from the Darlington Atrial Fibrillation Registry by M. Mazurek et al.
2198
One third of ischemic strokes and >80% of cardioem-bolic strokes are related to atrial fibrillation (AF).1 AF 
may also play a role in approximately a third of cryptogenic 
strokes, which account for 25% of all strokes.2 AF-related 
strokes result in a larger area of brain infarction and greater 
disability and mortality compared with strokes of other patho-
geneses.3 However, AF remains frequently under-recognized 
in patients who experience an acute stroke, and it is often left 
untreated in those with recent AF-related stroke despite high 
risk for stroke recurrence.1
AF-related strokes are highly preventable. A meta-analysis 
showed that oral anticoagulation (OAC) with vitamin K antag-
onists, such as warfarin, reduces the risk of stroke in patients 
with AF by 64% and mortality by 26% compared with placebo, 
whereas aspirin did not significantly decrease stroke risk and 
had no impact on mortality.4 Another meta-analysis demon-
strated that nonvitamin K antagonists OACs may offer addi-
tional stroke and mortality risk reduction by 19% and 10%, 
respectively, relative to warfarin.5 Consequently, in line with 
current AF guidelines, OAC should be offered to all patients 
with AF as a default practice unless a truly low-risk category 
is evident, that is, those with a CHA2DS2-VASc (congestive 
heart failure, hypertension, age ≥75 years, diabetes mellitus, 
stroke/transient ischemic attack, vascular disease, age 65–74 
years, sex category [female]) score=0 for men or CHA2DS2-
VASc=1 for women.6
Despite these recommendations, contemporary registry 
data show that more than half of AF patients with no stroke 
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risk factors are anticoagulated while at least a third of those 
at high risk of stroke do not receive OAC where indicated but 
instead are prescribed antiplatelet monotherapy or remain 
untreated.7 Importantly, lack of guideline adherence in anti-
thrombotic treatment for stroke prevention in AF has been 
shown to increase stroke/thromboembolic and mortality rates 
compared with recommended therapy.8–11
In contrast to previous data on guideline adherence for stroke 
prevention in AF predominantly implemented by cardiologists,7–10 
we present findings from 11 general practices in the United 
Kingdom serving the community cohort of 105 000 patients, of 
whom 2.15% (n=2259) had established AF diagnosis. Our objec-
tive was to assess clinical outcomes of community-based AF 
patients with versus without previous stroke in relation to guide-
line-adherent antithrombotic treatment for stroke prevention.
Materials and Methods
Study Population
The design of the Darlington AF Registry has been described pre-
viously.12 In brief, the study population comprised 105 000 patients 
living in Darlington, County Durham, United Kingdom, registered 
at 1 of 11 general practices. All patients with the diagnosis of AF or 
atrial flutter and known vital status in March 2013 were eligible for 
inclusion.
Data Collection
Guidance on Risk Assessment and Stroke Prevention in Atrial 
Fibrillation tool was used to collect data.12,13 All general practices in 
Darlington were equipped with this electronic record interrogation 
software that allowed for data collection on demographics, details 
of AF diagnosis, patient stroke risk profile and antithrombotic treat-
ment, and was primarily developed to facilitate decision making on 
stroke prevention therapies.
Because the Guidance on Risk Assessment and Stroke Prevention 
in Atrial Fibrillation tool does not collect data on clinical outcomes, 
separate searches of the database were performed to identify those 
patients who experienced acute stroke or died within 12 months. The 
Read Codes were used to identify different types of strokes, comor-
bidities, current therapies, and contraindications to treatment. All 
clinical events were manually reviewed and adjudicated.12
Definitions
Thromboembolic risk was assessed using the CHA2DS2-VASc 
score.14 Low-risk patients were men with CHA2DS2-VASc=0 and 
women with CHA2DS2-VASc=1 (1 point for sex category only); 
moderate-risk patients were men with CHA2DS2-VASc=1; and high-
risk patients were those with CHA2DS2-VASc score ≥2, irrespective 
of sex.
Antithrombotic treatment for stroke prevention was assessed 
against 2014 National Institute for Health and Care Excellence guide-
lines.6 Antithrombotic treatment was considered guideline adherent 
when the following criteria were applicable:
 – OAC in moderate- to high-risk patients with no reported contra-
indications to OAC therapy
 – no OAC in low-risk patients and those who refused treatment 
with OAC
 – OAC+antiplatelet therapy in moderate- to high-risk patients and 
acute vascular disease (ie, recent acute myocardial infarction)
Lack of guideline adherence in antithrombotic treatment was consid-
ered as either overtreatment (OAC overuse) or undertreatment (OAC 
underuse). Specifically, undertreatment was defined as no OAC (but 
antiplatelet or no therapy) in moderate- or high-risk patients and no 
reported contraindications or refusal to treatment. Overtreatment was 
defined as follows: OAC in low-risk patients or OAC+antiplatelet 
therapy in moderate- to high-risk patients with no evidence of acute 
vascular disease (ie, recent acute myocardial infarction); OAC in 
patients with reported contraindications to anticoagulation; or anti-
platelet agents in those who had reported contraindications to both 
OAC and antiplatelet therapy.
Of note, the American Heart Association/American College of 
Cardiology/Heart Rhythm Society guidelines differ with National 
Institute for Health and Care Excellence recommendations on stroke 
risk requiring anticoagulation, that is, OAC is recommended in 
patients with CHA2DS2-VASc score ≥2, whereas those with score 1 
may be offered OAC, aspirin, or even no stroke prophylaxis.15
Statistical Analysis
Categorical variables are presented as numbers and percentages, 
and continuous parameters as mean and SD. Baseline characteris-
tics, antithrombotic therapies, and clinical outcomes were tabulated 
in relation to prior stroke history. Multivariable logistic regression 
analyses were performed to determine independent predictors for 
new/recurrent stroke and all-cause death after adjustment for the 
components of the CHA2DS2-VASc score (age assessed as a con-
tinuous variable) and guideline-adherent or nonadherent (over-
treatment or undertreatment) antithrombotic treatment, and AF 
duration. The multivariable analysis was performed separately for 
patients with prior stroke history (secondary prevention group) and 
those without previous stroke (primary prevention group). All sta-
tistical analyses were performed using IBM SPSS Statistics (ver-
sion 21) software (Chicago, IL). Statistical significance was set at 
a 2-sided P<0.05.
Results
Overall, 2259 (2.15%) patients with AF were identified, of 
which 428 (18.9%) constituted a secondary prevention cohort. 
Patients with previous stroke were older, more often had 
comorbidities, and were at higher risk of stroke (all patients 
had CHA2DS2-VASc score ≥2, mean score of 5.5, SD of 1.28) 
as compared with those without prior stroke (CHA2DS2-VASc 
score ≥2 in 82.3%, mean score of 3.0, SD of 1.54; Table 1).
Overall, <50% of patients were prescribed anticoagula-
tion (46.4% vitamin K antagonists and 1.4% non-OACs) 
while 35.9% received antiplatelet therapy alone and 16.2% 
remained untreated (Table 1). Antithrombotic drug choice 
in relation to prior stroke history is summarized in Figure 1. 
Guideline-adherent antithrombotic treatment for stroke pre-
vention was applied more frequently in the secondary versus 
primary prevention cohort (56.3% versus 49.5%; P=0.011). 
Overtreatment was more common in patients with prior 
stroke, whereas undertreatment was more frequent in subjects 
with no stroke history (Table 1; Figure 2).
Based on the Read Codes, general practitioners reported 
contraindications to OAC therapy more frequently in patients 
with previous stroke (13.8%) compared with subjects with-
out prior stroke (7.0%; Table I in the online-only Data 
Supplement).
One-Year Outcomes
After 12 months of follow-up, the observed stroke rates were 
8.6% (n=37) and 1.6% (n=30) for the secondary and primary 
prevention cohorts, respectively (P<0.001). No difference was 
observed in the incidence of hemorrhagic strokes (0.2% in 
both groups; Table 2). All-cause death rates were comparable 
in patients with prior stroke (9.8%; n=42) and those without 
previous stroke (9.4%; n=172). The causes of death were also 
similar in both groups, except that in the secondary prevention 
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cohort, more patients died of noncerebral bleeding (0.5%; 
n=2) compared with the primary prevention cohort (0.1%; 
n=1; Table 2).
Clinical Outcomes in Relation to Guideline-
Adherent Antithrombotic Therapy
In the primary prevention group, the 1-year stroke rates 
were similar in guideline-adherent (0.8%) and overtreated 
patients (0.5%) while the undertreated patients had an ≈4-fold 
higher stroke rate (3.1%). The corresponding event rates for 
12-month all-cause mortality were 7.1%, 6.0%, and 13.2%, 
respectively (Table 3).
In the secondary prevention cohort, the lowest rate of stroke 
recurrence, at 5.4%, was in patients receiving guideline-rec-
ommended treatment, whereas the event rates for undertreat-
ment and overtreatment were 9.4% and 17.3%, respectively 
(P=0.011). There was no significant difference in all-cause 
mortality between guideline-adherent (6.6%) and overtreated 
patients (6.2%; P=0.88), whereas the mortality was 3-fold 
higher in the undertreated subjects (19.8%; P<0.001).
On multivariable logistic regression analysis (Table 4), non-
adherence with guideline-recommended antithrombotic treat-
ment was associated with an increased risk of stroke in the 
primary prevention cohort (odds ratio, 2.95; 95% confidence 
interval, 1.26–6.90; P=0.013 for undertreatment), whereas in 
the secondary prevention cohort, nonadherence with guide-
line-recommended antithrombotic treatment was associated 
with an increased risk of recurrent stroke (odds ratio, 2.80; 
95% confidence interval, 1.25–6.27; P=0.012 for overtreat-
ment) and all-cause death (odds ratio, 2.75; 95% confidence 
interval, 1.33–5.69; P=0.006 for undertreatment). No associa-
tion was found between AF duration and outcome events.
As a sensitivity analysis, the impact of OAC therapy per 
se on clinical outcomes after completely excluding patients 
who denied treatment or had any contraindications is shown 
in the online-only Data Supplement (Tables II and III in the 
online-only Data Supplement). The results show broadly simi-
lar trends as our principal analysis, with an even more pro-
nounced effect of OAC on outcomes.
Discussion
In this article, we provide antithrombotic treatment patterns 
in an unselected (ie, consecutive all-comers) contemporary, 
community-based AF population. The main findings of this 
study are that despite a high thromboembolic risk, particularly 
among secondary prevention patients, only ≈50% of patients 
with AF in primary care were prescribed OAC in line with 
guidelines. Second, guideline-adherent antithrombotic treat-
ment reduces the risk of stroke among primary prevention 
patients, and in those with prior stroke, there was a significant 
reduction in both recurrent stroke and mortality.
Several studies have found that guideline-adherent throm-
boprophylaxis in AF is associated with fewer stroke and 
lower mortality rates compared with nonguideline stroke 
prevention.8–11 However, these studies assessed adherence 
to guidelines in patients managed solely by cardiologists8–10 
or internal medicine specialists.11 Unlike in previous stud-
ies, we present findings from a community-based AF cohort 
managed by primary care physicians; however, it should be 
noted that the vast majority of strokes are diagnosed and 
managed in a hospital setting, and specialist input is pro-
vided at that stage, unless AF was not present at the time of 
the event. Our analysis also provides novel data on the clini-
cal implications of nonadherence with recommended anti-
thrombotic treatment for stroke prevention in AF and how 
this affects clinical outcomes in patients who have already 
experienced an acute stroke.
Table 1. Baseline Characteristics Overall and in the Primary 
and Secondary Prevention Groups
 All
Previous 
Stroke
No Previous 
Stroke P Value
n (%) 2259 (100) 428 (18.9) 1831 (81.1)  
Demographics
  Females 1041 (46.1) 193 (45.1) 848 (46.3) 0.68
  Age, y, mean (SD) 75.6 (12.2) 79.6 (9.6) 74.7 (12.6)  
   <65 367 (16.2) 28 (6.5) 339 (18.5)  
   65–74 554 (24.5) 93 (21.7) 461 (25.2)  
   ≥75 1338 (59.2) 307 (71.7) 1031 (56.3) <0.001
Medical history
  Heart failure 514 (22.8) 106 (24.8) 408 (22.3) 0.27
  Hypertension 1404 (62.2) 305 (71.3) 1099 (60.0) 0.001
  Diabetes mellitus 490 (21.7) 120 (28.0) 370 (20.2) 0.001
  Vascular disease 389 (17.2) 97 (22.7) 292 (15.9) 0.001
  Acute myocardial 
infarction
152 (6.7) 41 (9.6) 111 (6.1) 0.008
Thromboembolic risk
  CHA
2
DS
2
-VASc, 
mean (SD)
3.5 (1.79) 5.5 (1.28) 3.0 (1.54)  
  Score=0 118 (5.2) 0 118 (6.4)  
  Score=1 206 (9.1) 0 206 (11.6)  
  Score≥2 1935 (85.7) 428 (100) 1507 (82.3) <0.001
Antithrombotic treatment
  None 367 (16.2) 28 (6.5) 339 (18.5)  
  Antiplatelets 812 (35.9) 136 (31.8) 676 (36.9)  
  OAC 971 (43.0) 225 (52.6) 746 (40.7)  
  OAC+antiplatelets 109 (4.8) 39 (9.1) 70 (3.8) <0.001
Oral anticoagulation
  Contraindicated 187 (8.3) 59 (13.8) 128 (7.0) <0.001
  Declined 113 (5.0) 28 (6.5) 85 (4.6) 0.11
Antithrombotic therapy
  Guideline 
adherent
1147 (50.8) 241 (56.3) 906 (49.5) 0.011
  Overtreatment 296 (13.1) 81 (18.9) 215 (11.7) <0.001
  Undertreatment 816 (36.1) 106 (24.8) 710 (38.8) <0.001
CHA
2
DS
2
-VASc indicates congestive heart failure, hypertension, age ≥75 
years, diabetes mellitus, stroke/transient ischemic attack (TIA), vascular 
disease, age 65–74 years, sex category (female); and OAC, oral anticoagulant.
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As expected, we observed higher 1-year stroke rates in 
AF patients with versus without prior stroke. The magni-
tude of the stroke rate difference was 6-fold higher in sec-
ondary versus primary prevention patients, thereby reflecting 
a high thromboembolic risk among those with a previous 
stroke. Despite such high risk, only about half of the patients 
with prior strokes were prescribed OAC in line with current 
National Institute for Health and Care Excellence guidelines.6
More importantly, the lowest stroke recurrence was 
observed in patients who were guideline adherent, whereas it 
was higher for undertreatment and unexpectedly highest for 
overtreatment. Although higher stroke rates for overtreatment 
compared with guideline adherence may be surprising, the 
EORP-AF (EURObservational Research Programme Atrial 
Fibrillation) Pilot Registry also found a similar association 
between overtreatment and higher 1-year incidence of throm-
boembolic events, defined as any of the following: stroke, 
transient ischemic attack, acute coronary syndrome, coronary 
intervention, cardiac arrest, peripheral embolism, or pulmo-
nary embolism.10 By contrast, other studies have not reported 
such an association8,11 or have found a lower risk of thrombo-
embolism for overtreatment.9
The possible explanation of more is not better is not straight-
forward and may include various contributing factors. First, in 
contrast to the present analysis, none of other studies consid-
ered the presence of contraindications to antithrombotic treat-
ment or patient’s declining therapy when defining adherence 
versus nonadherence to antithrombotic treatment.8–11 Prior 
papers base OAC prescribing solely on thromboembolic 
risk (and thus, this assumes that 100% must be given OAC, 
no exceptions). Such an approach fails again to reflect real-
life everyday clinical practice by not taking into account an 
unselected population of consecutive patients, as well as many 
clinical- and patient-related factors affecting the final decision 
making needed for OAC prescribing. In addition, only the pres-
ent study and the EORP-AF registry corrected the definition of 
nonadherence for the presence of acute vascular disease.10
Second, although Gorin et al9 found significantly fewer 
event rates in overtreated patients and suggested that a more 
aggressive antithrombotic treatment (ie, combination of OAC 
and antiplatelet therapy) may be advocated in selected patients 
with AF, the authors used the older CHADS2 score (Congestive 
Heart Failure, Hypertension, Age≥75, Diabetes, Stroke/TIA) 
that resulted in classifying some patients as low-risk (ie, with 
Figure 1. Antithrombotic treatment in rela-
tion to prior stroke history. OAC indicates oral 
anticoagulation.
Figure 2. Antithrombotic treatment in relation to guideline adherence and prior stroke history. A, Prior stroke history. B, No prior stroke 
history. OAC indicates oral anticoagulation.
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CHADS2=0) and thus overtreated, whereas in the present anal-
ysis, many of them would be categorized as high-risk patients 
and consequently guideline adherent. In addition, overtreated 
patients were significantly younger and had lower risk of stroke 
compared with those undertreated or guideline adherent.9 By 
contrast, in the present analysis, overtreated versus guideline-
adherent patients were at significantly lower risk of stroke in 
the primary prevention while an opposite relation with a trend 
toward a higher thromboembolic risk was noted in the over-
treated, secondary prevention cohort.
Third, unlike previous studies, we analyzed the popula-
tion of AF patients with prior stroke, which are at the highest 
risk for stroke recurrence, 8.6% after 1 year of observation 
despite antithrombotic treatment. Our analysis did not show 
overtreatment to be associated with increased stroke rates in 
patients without prior stroke. Also, some physicians may con-
sider that combination therapy (OAC+antiplatelets) was more 
effective and superior to OAC monotherapy for stroke preven-
tion in patients with prior stroke. Our data suggest that despite 
such an aggressive antithrombotic treatment, the risk of stroke 
recurrence remains high. However, we may speculate that fear 
of bleeding complications while being more aggressive with 
antithrombotic treatment results in suboptimal quality of anti-
coagulation. For patients with AF undergoing percutaneous 
coronary interventions and thus requiring combination OAC 
and antiplatelet therapy, the average time in therapeutic range 
was only 52.6% with an international normalized ratio of 1.6 
to 2.6.16 Consequently, instead of a decrease in stroke rates, an 
increase in both stroke and major bleeding rates was observed 
when compared with patients who were not receiving combi-
nation antithrombotic treatment.
Nonetheless, despite stroke rates being 3× higher in 
the overtreated versus guideline-adherent group, we have 
observed similar mortality rates in both treatment cohorts. 
This finding would suggest that even though a more aggres-
sive antithrombotic regimen is not sufficient to protect against 
stroke recurrence in at high risk of stroke AF patients, while 
many of these strokes are not fatal, reduction in all-cause mor-
tality with antithrombotic therapy exceeds the reduction of 
stroke-related deaths only.17
Despite being at high risk for stroke, some patients may 
have genuine contraindications to anticoagulation because 
many stroke and bleeding risk factors do overlap.18 In the pres-
ent analysis, contraindications to OAC were reported in 13.8% 
and 7.0% of patients with versus without previous stroke, 
respectively. However, contraindications to OAC therapy are 
frequently not absolute and may be transient and depend on 
individually perceived lack of benefit from OAC prescription.6 
A considerable variation in the rates of reported contraindi-
cations to OAC (ranging from 2.6% to 12.0%) was observed 
across 1857 general practices in England.13 Contemporary 
registry data also show that ≈50% of eligible patients with AF 
are not offered OAC or have stroke prevention treatment dis-
continued because of physician’s preference.19,20 Many physi-
cians have concerns with regard to prescribing OAC to frail, 
elderly patients with many comorbidities, cognitive impair-
ment, and frequent falls21 although the available data show 
that even these patients, including the very elderly (>85 years 
of age), also benefit from anticoagulation.22,23
Bleeding risk assessment scores, such as the HAS-BLED 
(hypertension, abnormal renal and liver function, stroke, bleed-
ing, labile international normalized ratio s, age ≥65 years, 
Table 2. One-Year Outcomes Overall and in the Primary and 
Secondary Prevention Groups
 All
Previous 
Stroke
No Previous 
Stroke P Value
n (%) 2259 (100.0) 428 (18.9) 1831 (81.1)  
Recurrent/new stroke* 67 (3.0) 37 (8.6) 30 (1.6) <0.001
  Ischemic 62 (2.7) 36 (8.4) 26 (1.4)  
  Hemorrhagic 5 (0.2) 1 (0.2)† 4 (0.2)†  
Cause of death
  All-cause 214 (9.5) 42 (9.8)† 172 (9.4)† 0.79
  Cardiovascular
   Cardiac death 14 (0.6) 3 (0.7)† 11 (0.6)†  
   Heart failure 24 (1.1) 3 (0.7)† 21 (1.1)†  
   Stroke 11 (0.5) 3 (0.7)† 8 (0.4)†  
   PE or STE 3 (0.1) 1 (0.2)† 2 (0.1)†  
   Intracranial 
bleeding
5 (0.2) 1 (0.2)† 4 (0.2)†  
  Noncardiovascular
   Bleeding 
noncerebral
3 (0.1) 2 (0.5) 1 (0.1)  
   Cancer 42 (1.9) 4 (0.9)† 38 (2.1)†  
   Other 67 (3.0) 16 (3.7)† 51 (2.8)†  
   Unknown 45 (2.0) 9 (2.1)† 36 (2.0)†  
Values in the same row not sharing the same symbol (†) are significantly 
different at P<0.05. PE indicates pulmonary embolism; and STE, systemic 
thromboembolism.
*Confirmed by imaging (computer tomography was predominantly used).
Table 3. Event Rates at 1-Year in Relation to Prior Stroke 
History, Thromboembolic Risk, and Antithrombotic Guideline 
Adherence
n (%) Undertreatment
Adherent 
Treatment Overtreatment P Value
Prior stroke history n=106 n=241 n=81  
  CHA
2
DS
2
-VASc, 
mean (SD)
5.5 (1.40)* 5.5 (1.26)* 5.9 (1.11)* 0.050
  Recurrent stroke 10 (9.4)*,† 13 (5.4)* 14 (17.3)† 0.011
  All-cause death 21 (19.8) 16 (6.6)* 5 (6.2)* 0.006
No prior stroke n=710 n=906 n=215  
  CHA
2
DS
2
-VASc, 
mean (SD)
3.1 (1.39)* 3.2 (1.51)* 2.4 (1.95) <0.001
  New stroke 22 (3.1) 7 (0.8)* 1 (0.5)* 0.003
  All-cause death 94 (13.2) 65 (7.1)* 13 (6.0)* 0.003
Values in the same row not sharing the same symbol (*,†) are significantly 
different at P<0.05. CHA
2
DS
2
-VASc indicates congestive heart failure, 
hypertension, age ≥75 years, diabetes mellitus, stroke/transient ischemic 
attack (TIA), vascular disease, age 65–74 years, sex category (female).
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drugs or alcohol),6,24 were predominantly designed to flag up 
patients at increased risk for bleeding to allow for correction of 
the reversible risk factors (eg, uncontrolled hypertension, labile 
international normalized ratio values, concomitant drugs, alco-
hol abuse, etc)25 but were by no means intended to withhold or 
preclude OAC therapy.26 Importantly, the net clinical benefit of 
systemic anticoagulation, when balancing stroke risk reduc-
tion versus increased risk of bleeding, is still positive and even 
greater in patients at increased risk of bleeding.27 Therefore, once 
the reasons for interrupting OAC therapy have been corrected, a 
change from 1 anticoagulant to another may seem more reason-
able than complete withdrawal of OAC therapy, even in patients 
who have survived major bleeds or those with prior intracranial 
hemorrhage.28,29 Similarly, in patients who have experienced an 
ischemic stroke despite being on OAC, a switch to a more effec-
tive anticoagulant to prevent a recurrent thromboembolic event, 
that is, dabigatran 150 mg twice daily, could be considered.30
Foregoing anticoagulation may also result from patient’s 
refusal to use OAC. However, this shared decision making has 
to be based on detailed and clear explanation to a patient of 
their individual benefits and risks with OAC therapy.31 One 
recent study showed that 12% of patients with AF would refuse 
OAC even if it was 100% effective in preventing strokes while 
those who accepted anticoagulation were willing to accept 4.4 
major bleeds to prevent 1 stroke.32
Limitations and Strengths
A limitation of this study is that the analysis focused on 
the quantity but not quality of antithrombotic treatment. 
Despite having precise data on various antithrombotics 
used, as well as corrections made for antithrombotic drug 
uptake preceding the outcome events, neither international 
normalized ratio nor time in therapeutic range values were 
available. In addition, although the contraindications to, and 
reasons for patients declining antithrombotic therapy were 
reported precisely using Read codes, specific reasons for 
withholding or precluding OAC could not be identified. We 
could not establish the cause of death with certainty in 45 
patients because death certificates could not be retrieved. 
However, it is unlikely that any significant number of 
strokes were missed that way. It cannot be also excluded 
that some strokes were missed by being not coded although 
this is also unlikely as stroke rates contribute to the stroke 
prevalence recording, which is linked to therapy reimburse-
ment. Incorrect coding was addressed by a wide search of 
related conditions.
Although the cohort was a broad patient representation 
from 11 general practitioners practices serving the popula-
tion of >100 000 patients, it was confined to 1 UK region, 
and, therefore, the results may not be representative of other 
primary care populations in different regions. Unfortunately, 
data on sociodemographic characteristics were not available 
for the purpose of this analysis. However, in contrast to pre-
vious studies, we used precise and robust criteria for study 
end points used in randomized clinical trials, with stroke 
confirmed by cerebral imaging and every outcome event was 
manually adjudicated. The usefulness of the Guidance on Risk 
Assessment and Stroke Prevention in Atrial Fibrillation tool 
used for diagnostic and data collection purposes has been also 
previously confirmed.13
Our definition of adherence to guidelines is different 
from previously published papers because we have ana-
lyzed the unselected cohort of consecutive all-comers and 
thus included also those patients who declined OAC or had 
reported contraindications to therapy. We aimed to assess 
the impact of guideline adherence, rather than the specific 
impact of OAC therapy per se on clinical outcomes after 
completely excluding patients who denied treatment or had 
any contraindications. The results of the latter approach 
(broadly similar trends and showing even more pronounced 
effect of OAC on outcomes) have been summarized as a sen-
sitivity analysis.
Summary
Despite a high thromboembolic risk profile, particu-
larly among secondary prevention patients, only ≈50% of 
patients with AF in primary care are prescribed OAC in line 
Table 4. Multivariable Logistic Regression Analysis for New/
Recurrent Stroke and Death in Relation to Prior Stroke History
 
New Stroke
 OR (95% CI)
P 
Value
Death
 OR (95% CI) P Value
Prior stroke history
  Age (per 1-y 
increase)
1.00 (0.97–1.04) 0.83 1.08 (1.04–1.13) <0.001
  Female sex 1.32 (0.63–2.74) 0.46 1.02 (0.49–2.12) 0.96
  Hypertension 0.91 (0.43–1.95) 0.81 0.81 (0.38–1.72) 0.81
  Diabetes 
mellitus
1.72 (0.83–3.56) 0.14 2.21 (1.08–4.52) 0.03
  Heart failure 0.91 (0.39–2.12) 0.83 1.55 (0.73–3.30) 0.26
  Vascular 
disease
0.89 (0.38–2.10) 0.80 1.52 (0.70–3.28) 0.29
  ATT 
undertreatment
1.39 (0.58–3.30) 0.46 2.75 (1.33–5.69) 0.006
  ATT 
overtreatment
2.80 (1.25–6.27) 0.01 0.66 (0.23–1.89) 0.44
No prior stroke
  Age (per 1-y 
increase)
1.07 (1.03–1.12) 0.002 1.11 (1.09–1.14) <0.001
  Female sex 2.29 (0.96–5.50) 0.06 1.32 (0.91–1.91) 0.15
  Hypertension 0.79 (0.36–1.73) 0.56 0.97 (0.67–1.41) 0.88
  Diabetes 
mellitus
2.11 (0.94–4.73) 0.07 1.31 (0.88–1.97) 0.19
  Heart failure 1.38 (0.60–3.15) 0.44 2.11 (1.46–3.05) <0.001
  Vascular 
disease
2.12 (0.94–4.78) 0.07 3.28 (2.25–4.78) <0.001
  ATT 
undertreatment
2.95 (1.26–6.90) 0.01 1.36 (0.94–1.97) 0.10
  ATT 
overtreatment
0.56 (0.07–4.57) 0.58 0.83 (0.43–1.61) 0.58
ATT indicates antithrombotic treatment; CI, confidence interval; and OR, odds 
ratio.
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with current guidelines. Guideline-adherent antithrombotic 
therapy significantly reduces the risk of stroke among pri-
mary prevention patients, but in those with prior stroke, 
there is also a significant reduction in both recurrent stroke 
and death rates.
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